HOPKINTON, Mass., Oct. 12 /PRNewswire/ -- Caliper Life Sciences, Inc. (Nasdaq :CALP ), a leading provider of life science tools, announced today that it has renewed its supply agreement for microfluidics chips with Agilent Technologies. Under the new seven year supply agreement, Caliper will continue to be the exclusive supplier to Agilent of the microfluidic chips used in Agilent's Bioanalyzer 2100 platform.
"Agilent's success with the Bioanalyzer over the past decade affirms the importance of Caliper's microfluidics technologies to life sciences," said Kevin Hrusovsky, President and CEO of Caliper Life Science. "Agilent represents our largest OEM customer and accounted for over 15% of our total microfluidics business in 2009. We expect our microfluidics business to grow 10-15% in 2010, and the renewal of this relationship with its improved economics is a vital element of our strategy for sustainable double-digit growth in our microfluidics franchise over the long-term. We believe that our microfluidics technologies will continue growing as a critical tool for sample analysis as well as for sample preparation, particularly as sequencing and gene expression workflows become fundamental to the realization of personalized medicine."
Specific terms of the agreement were not disclosed. Since its introduction in 1999, Agilent has sold over 7,000 Bioanalyzer 2100 instruments worldwide and Caliper has supplied approximately 5 million chips for use on these instruments.
Microfluidic technology has enabled the development of instruments that have revolutionized clinical diagnostics, food testing, life science research and drug discovery by eliminating manual steps, improving data quality and reproducibility, lowering overall costs, and speeding time to results exponentially. Caliper owns or exclusively licenses a portfolio of over 400 issued US patents in the field of microfluidics.
About Caliper Life Sciences
Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results, enabling the translation of those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit www.caliperLS.com.
The statements in this press release regarding future events, including the statements regarding Caliper's belief that revenues of its microfluidics business will grow between 10- 15% in 2010, and on a double-digit basis over the long-term , as well as its belief that its microfluidic technology will continue to be a critical tool for sample analysis in life sciences research, are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements as a result of a number of factors, including that the demand for microfluidic chips for use on Agilent's Bioanalyzer 2100 platform may not be as strong as expected, or alternative technologies could be developed that displace Caliper's microfluidics technology. Further information on risks faced by Caliper are detailed under the caption "Risks Related to Our Business" in Caliper's Annual Report on Form 10-K for the year ended December 31, 2009. Our filings are available on a web site maintained by the Securities and Exchange Commission at http://www.sec.gov. Caliper does not undertake any obligation to update forward-looking or other statements in this release.
Caliper is a registered trademark of Caliper Life Sciences. Agilent is a registered trademark, and Bioanalyzer 2100 is an unregistered trademark, of Agilent Technologies.
SOURCE Caliper Life Sciences, Inc.